BioCentury
ARTICLE | Clinical News

Soltara norastemizole regulatory update

March 19, 2001 8:00 AM UTC

SEPR submitted an NDA for its third generation nonsedating antihistamine Soltara norastemizole to treat allergic rhinitis. SEPR developed Soltara with Johnson & Johnson (JNJ, New Brunswick, N.J.), wh...